Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Gyun-Ho Jeon
 -- 2398 2024-01-04 13:09:50 |
2 update references and layout
Rita Xu
 Meta information modification 2398 2024-01-05 02:30:02 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Jeon, G. Vitamin D with Ovarian Reserve Markers and Depression. Encyclopedia. Available online: https://encyclopedia.pub/entry/53426 (accessed on 03 May 2024).
Jeon G. Vitamin D with Ovarian Reserve Markers and Depression. Encyclopedia. Available at: https://encyclopedia.pub/entry/53426. Accessed May 03, 2024.
Jeon, Gyun-Ho. "Vitamin D with Ovarian Reserve Markers and Depression" Encyclopedia, https://encyclopedia.pub/entry/53426 (accessed May 03, 2024).
Jeon, G. (2024, January 04). Vitamin D with Ovarian Reserve Markers and Depression. In Encyclopedia. https://encyclopedia.pub/entry/53426
Jeon, Gyun-Ho. "Vitamin D with Ovarian Reserve Markers and Depression." Encyclopedia. Web. 04 January, 2024.
Vitamin D with Ovarian Reserve Markers and Depression
Edit
This entry is adapted from the peer-reviewed paper 10.3390/nu16010096

Since the identification of vitamin D receptors in both the female reproductive tract and the central nervous system, further data have shown that vitamin D is involved in the processes of reproductive and mental health.

vitamin D ovarian reserve anti-Müllerian hormone depression

1. Introduction

Vitamin D was initially known to be essential for bone health and calcium phosphorus homeostasis [1], but recent research suggests that it may also have important roles in blood pressure regulation, glucose control, wound healing, and immune function, and is even associated with cancer, autoimmune disease, obesity, etc. [2][3][4][5]. Furthermore, vitamin D also may act on the regulation of the microbiome, the modulation of immune and inflammatory processes, and the release of antimicrobial peptides. Vitamin D deficiency has also been associated with many pathologies, including inflammatory bowel disease, colorectal cancer, and sclerosis [6]. More recently, research on the role of vitamin D in female reproductive health and depression has increased as vitamin D receptors (VDRs) have been detected throughout the female reproductive system and central nervous system (CNS) [7][8]. The biological actions of vitamin D are applied through a VDR, which is a ligand-dependent transcription factor located in the nucleus of target cells [9]. The vitamin D-nuclear receptor complex then acts as a transcription factor and exerts a genomic effect on the ovary or brain [8][10]. Although the exact genomic effects on the target cells and the underlying mechanism by which vitamin D may be involved in reproductive and CNS systems are unknown, a direct association between vitamin D and ovarian steroidogenesis or brain-derived neurotrophic factor (BDNF) levels from in vitro and in vivo studies has been suggested [11][12][13]. In this context, several studies have been published on the relationship between vitamin D and ovarian reserve markers, BDNF, and neurotrophic factors [14][15], and there have also been many clinical reports that vitamin D deficiency is associated with reproductive hormonal decline or imbalances such as menopause, polycystic ovarian syndrome (PCOS), primary ovarian insufficiency (POI), and depression in women [16][17][18][19]. Meanwhile, the relationship between female reproductive hormone changes and depression is already well established [20][21], and several studies have shown that depression in female reproductive hormone-related diseases is also associated with low vitamin D levels and ovarian reserve markers [22][23]. In this regard, vitamin D, which is involved in both female hormones and depression, may be another key to explaining female reproductive depression.

2. The Association of Vitamin D and Ovarian Reserve Markers

Today, the most often used ovarian reserve marker is AMH, a gonadal-specific glycoprotein produced by granulosa cells of small antral or pre-antral follicles. AMH is also known to play a crucial role in folliculogenesis with minimal variations in its levels during the menstrual cycle, making it the most useful predictive marker for assisted reproductive technology [24]. Antral follicle counts (AFC) and basal follicular stimulation hormone (FSH) levels are also often used to represent ovarian reserve in clinical practice [25].

2.1. Basic Studies at the Cellular and Genetic Level

There has been increased interest in the potential relationship between vitamin D and ovarian reserve markers, particularly AMH, which is important for folliculogenesis, as reports about the effects of vitamin D on follicular development and steroidogenesis in animal and human cell-line studies have shown. For example, VDR null mutant mice not only have impaired folliculogenesis but also show uterine hypoplasia, decreased aromatase activity, aromatase gene expression, and increased FSH levels [7][11]. Also, vitamin D stimulates steroidogenesis in human ovarian cells [12]. However, there is limited information about how vitamin D affects ovarian reserve markers such as AMH. Malloy et al. demonstrated the presence of functional vitamin D response elements in the human AMH gene promotor region and a direct effect of vitamin D on AMH expression via these response elements [26]. Wojtusik et al. observed a dose-dependent decrease in AMH mRNA levels in hen granulosa cells after treatment with vitamin D [27]. In another recent study, treatment of human granulosa cells with vitamin D exhibited altered AMH signaling and an inverse correlation between vitamin D status in follicular fluid and AMH receptor-II (AMHR-II) mRNA gene expression [10]. Binding AMH to AMHR-II activates the type I transmembrane receptor and, subsequently, phosphorylation of Smad 1/5/8, which interacts with Smad 4, followed by this complex regulating transcription of the target gene after moving into the nucleus [28][29]. Binding AMH to AMHR-II is also known to suppress follicular maturation by inhibiting primordial follicle recruitment into the growing follicle pool and by decreasing the sensitivity of follicles to FSH [30]. Since vitamin D plays a role in the downregulation of AMHR-II gene expression, inhibiting the phosphorylation of Smad and its nuclear localization, it is suggested that vitamin D may promote follicle differentiation and development by altering AMH production patterns and FSH sensitivity in ovarian granulosa cells [31][32] (Figure 1). Indeed, Xu et al. showed that vitamin D sustained AMH production and enhanced the antral follicle growth in a rhesus monkey ovarian cell line study [33]. However, there was a discrepancy between these in vitro studies and clinical studies, which measured plasmatic levels of vitamin D and AMH. This might be due to the possibility that plasmatic levels do not reflect what inherently occurs in tissues. In this regard, there was a study on women with infertility that showed a strong negative correlation of 25-hydroxyvitamin D levels in blood and follicular fluid [34].
Figure 1. Mechanisms of the effects of vitamin D on AMH signaling and ovarian follicle development. Vitamin D alters the AMH signaling and actions by downregulation of AMHR-II gene expression (red box), inhibiting the phosphorylation of Smad and its nuclear localization, and can also promote follicle differentiation and development by altering AMH production patterns and FSH sensitivity in ovarian granulosa cells. FSH: follicle-stimulating hormone; AMH: anti-Müllerian hormone; AMHR-II: anti-Müllerian hormone receptor-II; mRNA: messenger ribonucleic acid; DNA: deoxyribonucleic acid; P: phosphate; ↑: increase; ↓: decrease.

2.2. Clinical Studies and Meta-Analyses

There have been several clinical observational and interventional studies showing significant relationships between vitamin D and ovarian reserve markers. In observational studies, a positive relationship between serum vitamin D and AMH levels was revealed in a cross-sectional study of 388 premenopausal women [35], and a negative correlation between serum vitamin D levels and urinary FSH levels was found in another study of 1430 premenopausal women [36], suggesting that lower vitamin D levels might be associated with lower ovarian reserve in late reproductive-age women (≥40 years) and earlier menopause. Dennis et al. also found that vitamin D might have a positive effect on AMH production in adults, and the seasonal changes in women’s AMH levels also correlates with those in vitamin D levels [37]. In recent interventional studies, improvements in ovarian reserve markers were reported with vitamin D supplementation, supporting a possible favorable effect of vitamin D on ovarian reserve markers [38][39]. However, there were also other studies that revealed no significant association between vitamin D and ovarian reserve markers, such as AMH and AFC [14][40][41]. Therefore, vitamin D still seems to have inconsistent evidence regarding its relation with ovarian reserves. Nonetheless, it is noteworthy that some recent studies, including meta-analyses, have reported promising results showing that vitamin D supplementation led to improvement in ovarian reserve metrics in a subgroup of normal or diminished ovarian reserves. There were three recent meta-analyses published between 2020 and 2022, two of which provided evidence that vitamin D supplements lead to improved ovarian reserve levels in a subgroup of non-PCOS women with normal ovulation or diminished ovarian reserves [42][43], and one found that lower AFC was associated with vitamin D insufficiency/deficiency in a subgroup analysis of Asians [44]. Moridi et al. highlighted that 18 cross-sectional studies had discrepant findings regarding an association between serum vitamin D and AMH levels, which is likely due to heterogeneity in study subjects and the complex nonlinear relationship between vitamin D and AMH in the systematic review. In contrast, they also demonstrated a cause–effect relationship between vitamin D supplements and AMH in the meta-analysis of six interventional studies, in which, interestingly, serum AMH was significantly increased in ovulatory non-PCOS women and decreased in PCOS patients after vitamin D supplementation [42]. Similarly, in other meta-analyses, vitamin D supplements led to an increase in AMH levels in non-PCOS women but no increase in AMH levels in PCOS patients [43].
The role of vitamin D in women with PCOS is even more noteworthy, considering that PCOS can be commonly accompanied by vitamin D deficiency in 67–85% of cases [45]. Vitamin D supplementation has been reported to reduce serum androgen and AMH levels and endometrial thickness [46] and to improve fertility indicators by increasing endometrial VDR expression and improving endometrial receptivity [47][48]. Zhao et al. showed that both implantation and clinical pregnancy occurrence were significantly higher in patients with normal vitamin D levels compared to patients with decreased vitamin D levels and that the number of high-quality embryos after vitamin D supplements was equivalent to the number of embryos in women with normal vitamin D levels [49].

3. The Association of Vitamin D and Depression

Observational studies have suggested that women with low vitamin D levels are predisposed to PCOS, infertility, and endometriosis [50], as well as psychological disorders such as depression [51]. Women with reproductive diseases that affect fertility are known to have a higher prevalence of depression [52], so the relationship between vitamin D and depression in relation to fertility is also noteworthy. It is proposed that various mechanisms are involved in the pathogenesis of depression, including those affecting neuroendocrine, immunologic, neurotrophic, and metabolic systems [53]. Vitamin D is also thought to have a variety of functions, such as neuroimmunomodulation, regulation of neurotrophin, and neuroplasticity, in the brain [54] and to be involved in serotonin synthesis and maintenance of the circadian rhythm [55]. Moreover, VDR was found in neurons and glia in many regions of the brain (prefrontal cortex, substantia nigra, cingulate cortex, hippocampus, and hypothalamus) that may play a role in the pathophysiology of depression [8], and vitamin D is biologically suggested to not only be involved in the synthesis of neurotransmitters such as serotonin, dopamine, adrenalin, and noradrenalin through VDR but also to moderate the hypothalamic–pituitary–adrenal axis (HPA) and γ-aminobutyric acid A (GABA-A) receptor activity [56].

3.1. Basic Studies in Cellular and Genetic Level

Although the pathophysiology of how vitamin D affects depression has not yet been fully elucidated, several main mechanisms have been reported. First, VDR and 1-α-hydroxylase (vitamin D activating enzyme) are widely distributed in the brain, especially in the hippocampus, which plays a key role in the mechanisms of depression [57]. Numerous studies conducted on in vitro hippocampal cells and in vivo adult rodents have shown that vitamin D deficiency alters the structure or function of the hippocampus during development [58]. Additionally, it has been demonstrated that vitamin D can regulate neurotrophins such as nerve growth factor (NGF), BDNF, and neurotrophin (NT)-3, which are essential for the survival and differentiation of neurons during development [59]. It has been reported that vitamin D may affect depression by increasing BDNF, which plays an important role in the survival, differentiation, and function of newborn neurons in the adult hippocampus [13][60]. Second, vitamin D could influence serotonin synthesis by alleviating tryptophan hydroxylase 2 (TPH2) and repressing tryptophan hydroxylase 1 (TPH1). It thus has an antidepressant effect by modulating the serotonergic system [61][62]. A strong body of evidence of the role of serotonin in the pathophysiology of depression has been built, and serotonin also acts on the hippocampus [63]. Vitamin D is known to be involved in depression by also affecting the levels of dopamine and noradrenalin [64]. Third, vitamin D is thought to control inflammation by reducing the expression of inflammatory cytokines, exhibiting a neuroprotective effect [65]. Grudet et al. have also shown that vitamin D insufficiency increased inflammatory markers such as IL-1β and IL-6 in depressive rats, although the underlying mechanisms are not clear yet [66]. In addition, vitamin D has been reported to be related to depression through mechanisms such as antioxidant effects in the CNS, regulation of expression of calcium homeostasis genes, regulation of mitochondrial protein expression, and regulation of demethylation, but additional studies and evidence seem to be necessary for further understanding [60].

3.2. Clinical Studies and Meta-Analyses on Cohort and Interventional Studies

There have been numerous observational studies on the relationship between serum vitamin D and depression and interventional studies on the effect of vitamin D supplements on depression. Several meta-analyses have also been conducted, which reflects the strong interest in the role of vitamin D. Observational studies have generally suggested an association between low serum vitamin D levels and depression. Vitamin D deficiency was related to depression-like symptoms, and subjects with anxiety or depression showed lower serum vitamin D levels [51][67]. Seasonal affective disorder was also suggested to be related to low vitamin D levels in northern latitudes with less sunlight exposure and in winter [68]. However, recent studies have failed to prove this relationship in female or elderly populations [69][70]. These discrepancies may result from not considering possible modulating factors such as subject characteristics and sociodemographic factors (sex, body mass index, diet, underlying diseases, drinking and smoking, etc.) and limitations of cross-sectional studies (biases caused by reverse causality: low vitamin D due to less outdoor activity/reduced nutrient intake, self-scored depression, unadjusted data, etc.). Interventional studies on the effect of vitamin D supplements in reducing depression have also provided inconsistent results. In this regard, several meta-analyses of randomized controlled trials (RCTs) of depressive patients were conducted, and some found a positive effect of vitamin D on depression severity [71][72], while others showed insignificant vitamin D efficacy for depressive symptoms [73][74]. However, interpretation of these results should also take into account that they also did not examine some factors that may modulate the efficacy of vitamin D in different settings. Also, considering there is reciprocity between vitamin D and epigenetic mechanisms [75], there may be a complex nonlinear relationship between vitamin D and reproduction or depression due to epigenetic changes caused by vitamin D supplementation. Recently, Musazadeh et al. conducted an umbrella meta-analysis on ten meta-analyses of interventional RCTs and four meta-analyses of cohort observational studies [76]. This umbrella meta-analysis demonstrated a significant reduction in depressive symptoms in patients with vitamin D supplements and increased odds of depression in patients with low serum vitamin D levels. In another recent meta-analysis of 18 RCTs, vitamin D supplements were effective in depressed patients in heterogeneous data [77]. In these two recent meta-analyses, there were subgroup analyses of several factors that might modulate vitamin D efficacy, and no differences in the efficacy of vitamin D supplementation according to gender were observed, suggesting that vitamin D supplementation is beneficial to both men and women [76][77]. To date, there is growing promise that low vitamin D levels are related to the risk of depression and that vitamin D supplementation may be effective in treating depression.

References

  1. Holick, M.F. Vitamin D Deficiency. N. Engl. J. Med. 2007, 357, 266–281.
  2. Laird, E.; Ward, M.; McSorley, E.; Strain, J.J.; Wallace, J. Vitamin D and Bone Health; Potential Mechanisms. Nutrients 2010, 2, 693–724.
  3. Amrein, K.; Scherkl, M.; Hoffmann, M.; Neuwersch-Sommeregger, S.; Köstenberger, M.; Berisha, A.T.; Martucci, G.; Pilz, S.; Malle, O. Vitamin D deficiency 2.0: An update on the current status worldwide. Eur. J. Clin. Nutr. 2020, 74, 1498–1513.
  4. Gandini, S.; Boniol, M.; Haukka, J.; Byrnes, G.; Cox, B.; Sneyd, M.J.; Mullie, P.; Autier, P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer 2011, 128, 1414–1424.
  5. Bikle, D.D. Role of vitamin D and calcium signaling in epidermal wound healing. J. Endocrinol. Investig. 2022, 46, 205–212.
  6. Barbalho, S.M.; Goulart, R.d.A.; Araújo, A.C.; Guiguer, L.; Bechara, M.D. Irritable bowel syndrome: A review of the general aspects and the potential role of vitamin D. Expert Rev. Gastroenterol. Hepatol. 2019, 13, 345–359.
  7. Kinuta, K.; Tanaka, H.; Moriwake, T.; Aya, K.; Kato, S.; Seino, Y. Vitamin D Is an Important Factor in Estrogen Biosynthesis of Both Female and Male Gonads. Endocrinology 2000, 141, 1317–1324.
  8. Eyles, D.W.; Smith, S.; Kinobe, R.; Hewison, M.; McGrath, J.J. Distribution of the Vitamin D receptor and 1 α-hydroxylase in human brain. J. Chem. Neuroanat. 2005, 29, 21–30.
  9. Carlberg, C.; Polly, P. Gene Regulation by Vitamin D3. Crit. Rev. Eukaryot. Gene Expr. 1998, 8, 19–42.
  10. Merhi, Z.; Doswell, A.; Krebs, K.; Cipolla, M. Vitamin D Alters Genes Involved in Follicular Development and Steroidogenesis in Human Cumulus Granulosa Cells. J. Clin. Endocrinol. Metab. 2014, 99, E1137–E1145.
  11. Yoshizawa, T.; Handa, Y.; Uematsu, Y.; Takeda, S.; Sekine, K.; Yoshihara, Y.; Kawakami, T.; Arioka, K.; Sato, H.; Uchiyama, Y.; et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 1997, 16, 391–396.
  12. Parikh, G.; Varadinova, M.; Suwandhi, P.; Araki, T.; Rosenwaks, Z.; Poretsky, L.; Seto-Young, D. Vitamin D Regulates Steroidogenesis and Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) Production in Human Ovarian Cells. Horm. Metab. Res. 2010, 42, 754–757.
  13. Koshkina, A.; Dudnichenko, T.; Baranenko, D.; Fedotova, J.; Drago, F. Effects of Vitamin D3 in Long-Term Ovariectomized Rats Subjected to Chronic Unpredictable Mild Stress: BDNF, NT-3, and NT-4 Implications. Nutrients 2019, 11, 1726.
  14. Kim, G.-M.; Jeon, G.-H. Serum vitamin D levels and ovarian reserve markers in secondary amenorrhea patients: Is there a link? Obstet. Gynecol. Sci. 2020, 63, 521–528.
  15. Abiri, B.; Sarbakhsh, P.; Vafa, M. Randomized study of the effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammation, and SIRT1 in obese women with mild to moderate depressive symptoms. Nutr. Neurosci. 2022, 25, 2123–2135.
  16. López-Baena, M.T.; Pérez-Roncero, G.R.; Pérez-López, F.R.; Mezones-Holguín, E.; Chedraui, P. Vitamin D, menopause, and aging: Quo vadis? Climacteric 2020, 23, 123–129.
  17. Cooney, L.G.; Lee, I.; Sammel, M.D.; Dokras, A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: A systematic review and meta-analysis. Hum. Reprod. 2017, 32, 1075–1091.
  18. Allshouse, A.A.; Semple, A.L.; Santoro, N.F. Evidence for prolonged and unique amenorrhea-related symptoms in women with premature ovarian failure/primary ovarian insufficiency. Menopause 2015, 22, 166–174.
  19. Milaneschi, Y.; Shardell, M.; Corsi, A.M.; Vazzana, R.; Bandinelli, S.; Guralnik, J.M.; Ferrucci, L. Serum 25-Hydroxyvitamin D and Depressive Symptoms in Older Women and Men. J. Clin. Endocrinol. Metab. 2010, 95, 3225–3233.
  20. García-Portilla, M.P. Depression and perimenopause: A review. Actas Esp. Psiquiatr. 2009, 37, 213–221.
  21. Studd, J.; Nappi, R.E. Reproductive depression. Gynecol. Endocrinol. 2012, 28 (Suppl. S1), 42–45.
  22. Kim, G.-M.; Jeon, G.-H. Correlation between Serum 25-Hydroxyvitamin D Level and Depression among Korean Women with Secondary Amenorrhea: A Cross-Sectional Observational Study. Nutrients 2022, 14, 2835.
  23. Zhang, W.-Y.; Guo, Y.-J.; Wang, K.-Y.; Chen, L.-M.; Jiang, P. Neuroprotective effects of vitamin D and 17ß-estradiol against ovariectomy-induced neuroinflammation and depressive-like state: Role of the AMPK/NF-κB pathway. Int. Immunopharmacol. 2020, 86, 106734.
  24. Zec, I.; Tislaric-Medenjak, D.; Megla, Z.B.; Kucak, I. Anti-Müllerian hormone: A unique biochemical marker of gonadal development and fertility in humans. Biochem. Med. 2011, 21, 219–230.
  25. Tal, R.; Seifer, D.B. Ovarian reserve testing: A user’s guide. Am. J. Obstet. Gynecol. 2017, 217, 129–140.
  26. Malloy, P.J.; Peng, L.; Wang, J.; Feldman, D. Interaction of the Vitamin D Receptor with a Vitamin D Response Element in the Müllerian-Inhibiting Substance (MIS) Promoter: Regulation of MIS Expression by Calcitriol in Prostate Cancer Cells. Endocrinology 2009, 150, 1580–1587.
  27. Wojtusik, J.; Johnson, P.A.; Wu, Y.; He, Z.; Zhang, L.; Jiang, H.; Zhang, W. Vitamin D Regulates Anti-Mullerian Hormone Expression in Granulosa Cells of the Hen1. Biol. Reprod. 2012, 86, 91.
  28. Massagué, J.; Gomis, R.R. The logic of TGFβ signaling. FEBS Lett. 2006, 580, 2811–2820.
  29. Massagué, J.; Seoane, J.; Wotton, D. Smad transcription factors. Genes Dev. 2005, 19, 2783–2810.
  30. Durlinger, A.L.; Visser, J.A.; Themmen, A.P. Regulation of ovarian function: The role of anti-Mullerian hormone. Reproduction 2002, 124, 601–609.
  31. Visser, J. Role of anti-Müllerian hormone in follicle recruitment and maturation. J. Gynecol. Obstet. Biol. Reprod 2006, 35, 2s30–32s34.
  32. Irani, M.; Merhi, Z. Role of vitamin D in ovarian physiology and its implication in reproduction: A systematic review. Fertil. Steril. 2014, 102, 460–468.e3.
  33. Xu, J.; Hennebold, J.D.; Seifer, D.B. Direct vitamin D3 actions on rhesus macaque follicles in three-dimensional culture: Assessment of follicle survival, growth, steroid, and antimüllerian hormone production. Fertil. Steril. 2016, 106, 1815–1820.e1811.
  34. Bednarska-Czerwińska, A.; Olszak-Wąsik, K.; Olejek, A.; Czerwiński, M.; Tukiendorf, A.A. Vitamin D and Anti-Müllerian Hormone Levels in Infertility Treatment: The Change-Point Problem. Nutrients 2019, 11, 1053.
  35. Merhi, Z.O.; Seifer, D.B.; Weedon, J.; Adeyemi, O.; Holman, S.; Anastos, K.; Golub, E.T.; Young, M.; Karim, R.; Greenblatt, R.; et al. Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women’s Interagency HIV Study. Fertil. Steril. 2012, 98, 228–234.
  36. Jukic, A.M.Z.; Steiner, A.Z.; Baird, D.D. Association between serum 25-hydroxyvitamin D and ovarian reserve in premenopausal women. Menopause 2015, 22, 312–316.
  37. Dennis, N.A.; Houghton, L.A.; Jones, G.T.; Van Rij, A.M.; Morgan, K.; McLennan, I.S. The Level of Serum Anti-Müllerian Hormone Correlates with Vitamin D Status in Men and Women but Not in Boys. J. Clin. Endocrinol. Metab. 2012, 97, 2450–2455.
  38. Bacanakgil, B.H.; İlhan, G.; Ohanoğlu, K. Effects of vitamin D supplementation on ovarian reserve markers in infertile women with diminished ovarian reserve. Medicine 2022, 101, e28796.
  39. Aramesh, S.; Alifarja, T.; Jannesar, R.; Ghaffari, P.; Vanda, R.; Bazarganipour, F. Does vitamin D supplementation improve ovarian reserve in women with diminished ovarian reserve and vitamin D deficiency: A before-and-after intervention study. BMC Endocr. Disord. 2021, 21, 126.
  40. Drakopoulos, P.; van de Vijver, A.; Schutyser, V.; Milatovic, S.; Anckaert, E.; Schiettecatte, J.; Blockeel, C.; Camus, M.; Tournaye, H.; Polyzos, N.P. The effect of serum vitamin D levels on ovarian reserve markers: A prospective cross-sectional study. Hum. Reprod. 2017, 32, 208–214.
  41. Shapiro, A.J.; Darmon, S.K.; Barad, D.H.; Gleicher, N.; Kushnir, V.A. Vitamin D levels are not associated with ovarian reserve in a group of infertile women with a high prevalance of diminished ovarian reserve. Fertil. Steril. 2018, 110, 761–766.e1.
  42. Moridi, I.; Chen, A.; Tal, O.; Tal, R. The Association between Vitamin D and Anti-Müllerian Hormone: A Systematic Review and Meta-Analysis. Nutrients 2020, 12, 1567.
  43. Yin, W.-W.; Huang, C.-C.; Chen, Y.-R.; Yu, D.-Q.; Jin, M.; Feng, C. The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: A meta-analysis. BMC Endocr. Disord. 2022, 22, 158.
  44. Karimi, E.; Arab, A.; Rafiee, M.; Amani, R. A systematic review and meta-analysis of the association between vitamin D and ovarian reserve. Sci. Rep. 2021, 11, 16005.
  45. Thomson, R.L.; Spedding, S.; Buckley, J.D. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin. Endocrinol. 2012, 77, 343–350.
  46. Kuyucu, Y.; Çelik, L.S.; Kendirlinan, Ö.; Tap, Ö.; Mete, U. Investigation of the uterine structural changes in the experimental model with polycystic ovary syndrome and effects of vitamin D treatment: An ultrastructural and immunohistochemical study. Reprod. Biol. 2018, 18, 53–59.
  47. Guo, J.; Liu, S.; Wang, P.; Ren, H.; Li, Y. Characterization of VDR and CYP27B1 expression in the endometrium during the menstrual cycle before embryo transfer: Implications for endometrial receptivity. Reprod. Biol. Endocrinol. 2020, 18, 24.
  48. Menichini, D.; Forte, G.; Orrù, B.; Gullo, G.; Unfer, V.; Facchinetti, F. The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review. Int. J. Vitam. Nutr. Res. 2022, 92, 126–133.
  49. Zhao, J.; Liu, S.; Wang, Y.; Wang, P.; Qu, D.; Liu, M.; Ma, W.; Li, Y. Vitamin D improves in-vitro fertilization outcomes in infertile women with polycystic ovary syndrome and insulin resistance. Minerva Med. 2019, 110, 199–208.
  50. Colonese, F.; Laganà, A.S.; Colonese, E.; Sofo, V.; Salmeri, F.M.; Granese, R.; Triolo, O. The Pleiotropic Effects of Vitamin D in Gynaecological and Obstetric Diseases: An Overview on a Hot Topic. BioMed. Res. Int. 2015, 2015, 98628.
  51. Bičíková, M.; Dušková, M.; Vítků, J.; Kalvachová, B.; Řípová, D.; Mohr, P.; Stárka, L. Vitamin D in Anxiety and Affective Disorders. Physiol. Res. 2015, 64, S101–S103.
  52. Kiani, Z.; Simbar, M.; Hajian, S.; Zayeri, F. The prevalence of depression symptoms among infertile women: A systematic review and meta-analysis. Fertil. Res. Pract. 2021, 7, 6.
  53. Strawbridge, R.; Young, A.H.; Cleare, A.J. Biomarkers for depression: Recent insights, current challenges and future prospects. Neuropsychiatr. Dis. Treat. 2017, 13, 1245–1262.
  54. Fernandes de Abreu, D.A.; Eyles, D.; Féron, F. Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 2009, 34 (Suppl. S1), S265–S277.
  55. Casseb, G.A.S.; Kaster, M.P.; Rodrigues, A.L.S. Potential Role of Vitamin D for the Management of Depression and Anxiety. CNS Drugs 2019, 33, 619–637.
  56. Spedding, S. Vitamin D and Depression: A Systematic Review and Meta-Analysis Comparing Studies with and without Biological Flaws. Nutrients 2014, 6, 1501–1518.
  57. Lardner, A.L. Vitamin D and hippocampal development-the story so far. Front. Mol. Neurosci. 2015, 8, 58.
  58. Holick, M.F. Vitamin D Status: Measurement, Interpretation, and Clinical Application. Ann. Epidemiology 2009, 19, 73–78.
  59. Zhang, J.-C.; Yao, W.; Hashimoto, K. Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets. Curr. Neuropharmacol. 2016, 14, 721–731.
  60. Geng, C.; Shaikh, A.S.; Han, W.; Chen, D.; Guo, Y.; Jiang, P. Vitamin D and depression: Mechanisms, determination and application. Asia Pac. J. Clin. Nutr. 2019, 28, 689–694.
  61. Patrick, R.P.; Ames, B.N. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: Relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. FASEB J. 2015, 29, 2207–2222.
  62. Neis, V.B.; Werle, I.; Moretti, M.; Rosa, P.B.; Camargo, A.; Dalsenter, Y.d.O.; Platt, N.; Rosado, A.F.; Engel, W.D.; de Almeida, G.R.L.; et al. Involvement of serotonergic neurotransmission in the antidepressant-like effect elicited by cholecalciferol in the chronic unpredictable stress model in mice. Metab. Brain Dis. 2022, 37, 1597–1608.
  63. Jeon, S.W.; Kim, Y.-K. Molecular Neurobiology and Promising New Treatment in Depression. Int. J. Mol. Sci. 2016, 17, 381.
  64. El Mansari, M.; Guiard, B.P.; Chernoloz, O.; Ghanbari, R.; Katz, N.; Blier, P. Relevance of Norepinephrine–Dopamine Interactions in the Treatment of Major Depressive Disorder. CNS Neurosci. Ther. 2010, 16, e1–e17.
  65. Wei, R.; Christakos, S. Mechanisms Underlying the Regulation of Innate and Adaptive Immunity by Vitamin D. Nutrients 2015, 7, 8251–8260.
  66. Grudet, C.; Malm, J.; Westrin, A.; Brundin, L. Suicidal patients are deficient in vitamin D, associated with a pro-inflammatory status in the blood. Psychoneuroendocrinology 2014, 50, 210–219.
  67. Di Gessa, G.; Biddulph, J.P.; Zaninotto, P.; de Oliveira, C. Changes in vitamin D levels and depressive symptoms in later life in England. Sci. Rep. 2021, 11, 7724.
  68. Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin; Calcium, D. Dietary Reference Intakes for Calcium and Vitamin D; The National Academies Collection: Reports funded by National Institutes of Health; Ross, A.C., Taylor, C.L., Yaktine, A.L., Del Valle, H.B., Eds.; National Academies Press: Washington, DC, USA, 2011.
  69. Rhee, S.J.; Lee, H.; Ahn, Y.M. Serum Vitamin D Concentrations Are Associated with Depressive Symptoms in Men: The Sixth Korea National Health and Nutrition Examination Survey 2014. Front. Psychiatry 2020, 11, 756.
  70. Pan, A.; Lu, L.; Franco, O.H.; Yu, Z.; Li, H.; Lin, X. Association between depressive symptoms and 25-hydroxyvitamin D in middle-aged and elderly Chinese. J. Affect. Disord. 2009, 118, 240–243.
  71. Mikola, T.; Marx, W.; Lane, M.M.; Hockey, M.; Loughman, A.; Rajapolvi, S.; Rocks, T.; O’neil, A.; Mischoulon, D.; Valkonen-Korhonen, M.; et al. The effect of vitamin D supplementation on depressive symptoms in adults: A systematic review and meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr. 2022, 63, 11784–11801.
  72. Menon, V.; Vellekkatt, F.; Menon, V. Efficacy of vitamin D supplementation in major depression: A meta-analysis of randomized controlled trials. J. Postgrad. Med. 2019, 65, 74–80.
  73. Tomé, A.L.; Cebriá, M.J.R.; González-Teruel, A.; Carbonell-Asíns, J.A.; Nicolás, C.C.; Hernández-Viadel, M. Efficacy of vitamin D in the treatment of depression: A systematic review and meta-analysis. Actas. Esp. Psiquiatr. 2021, 49, 12–23.
  74. Cheng, Y.C.; Huang, Y.C.; Huang, W.L. The effect of vitamin D supplement on negative emotions: A systematic review and meta-analysis. Depress. Anxiety 2020, 37, 549–564.
  75. Snegarova, V.; Naydenova, D. Vitamin D: A Review of its Effects on Epigenetics and Gene Regulation. Folia Med. 2020, 62, 662–668.
  76. Musazadeh, V.; Keramati, M.; Ghalichi, F.; Kavyani, Z.; Ghoreishi, Z.; Alras, K.A.; Albadawi, N.; Salem, A.; Albadawi, M.I.; Salem, R.; et al. Vitamin D protects against depression: Evidence from an umbrella meta-analysis on interventional and observational meta-analyses. Pharmacol. Res. 2023, 187, 106605.
  77. Srifuengfung, M.; Srifuengfung, S.; Pummangura, C.; Pattanaseri, K.; Oon-Arom, A.; Srisurapanont, M. Efficacy and acceptability of vitamin D supplements for depressed patients: A systematic review and meta-analysis of randomized controlled trials. Nutrition 2023, 108, 111968.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Obstetrics & Gynaecology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Gyun-Ho Jeon
View Times: 83
Revisions: 2 times (View History)
Update Date: 05 Jan 2024
Table of Contents
    1000/1000
    Hot Most Recent
    Feedback